Vagus Nerve Stimulation for Inflammatory Bowel Disease: What the Research Shows

Introduction: A Promising Direction, Honestly Assessed

Inflammatory bowel disease (IBD) — chiefly Crohn's disease and ulcerative colitis — is a chronic condition in which the immune system drives damaging inflammation in the gut. Because the vagus nerve links the brain to the digestive tract and helps regulate inflammation, it has become an active target for researchers seeking new ways to control IBD. The early results are genuinely encouraging. They are also small, preliminary, and in places uncontrolled — and both of those things are true at once.

This article describes what the trials have found, and is careful to distinguish a promising signal from a proven treatment. The short version: a handful of small studies suggest vagus nerve stimulation (VNS) can reduce inflammation and improve symptoms in some people with IBD, but the evidence is at an early, proof-of-concept stage and does not yet support it as a standard therapy. Interest is driven partly by a real clinical need: a meaningful proportion of people with IBD lose response to, or cannot tolerate, existing biologic drugs, which makes a mechanistically different option appealing — provided it can be shown to work.

The Gut, the Vagus Nerve, and Inflammation

The rationale draws on the vagus nerve's dual role as both a communication line and an immune regulator. As Bonaz, Bazin and Pellissier (2018) describe, the vagus nerve sits "at the interface of the microbiota-gut-brain axis" — relaying signals between the gut and brain, influencing the gut microbiota and the integrity of the intestinal barrier, and participating in the control of gut inflammation.

That inflammatory control runs through the cholinergic anti-inflammatory pathway, the same circuit first characterised by Tracey (2002), in which vagal activity restrains the release of pro-inflammatory cytokines. Because IBD is fundamentally a disease of excessive, dysregulated gut inflammation, the hypothesis was straightforward: if vagal tone helps keep inflammation in check, perhaps stimulating the nerve could help restore that control. This mechanism is explored more broadly in our articles on gut health and inflammation.

Bonaz 2016: First-in-Human VNS for Crohn's Disease

The first human evidence came from Bonaz et al. (2016), a pilot study published in Neurogastroenterology & Motility. Seven patients with active Crohn's disease received a surgically implanted vagus nerve stimulator and were followed for six months. The results were encouraging: most patients showed improvement across clinical measures (Crohn's Disease Activity Index), biological markers of inflammation (such as C-reactive protein and faecal calprotectin), and in some cases endoscopic appearance, alongside signs of restored vagal tone.

This was an important early demonstration — but with only seven patients and no sham control, it could establish feasibility and a plausible signal, not efficacy. It was, in the truest sense, a first step.

Sahn 2023: Non-Invasive taVNS in Paediatric IBD

A more recent study moved to the non-invasive approach. Sahn et al. (2023), in Bioelectronic Medicine, conducted a proof-of-concept trial of transcutaneous auricular VNS (taVNS) in 22 children and young people with IBD (10 with Crohn's disease, 12 with ulcerative colitis). The design combined a brief sham-controlled crossover phase with a longer open-label phase of twice-daily active stimulation over 16 weeks.

By week 16, clinical remission was reported in 50% of symptomatic Crohn's patients and 33% of symptomatic ulcerative colitis patients, and among those with elevated baseline faecal calprotectin, roughly two-thirds (64.7%) achieved at least a 50% reduction in this marker of gut inflammation. The intervention was well tolerated.

These are meaningful improvements in a young population — but the efficacy phase was largely open-label (everyone knew they were receiving active stimulation), which means placebo effects and natural fluctuation in disease activity cannot be excluded. The authors framed it accurately: proof of concept, not proof of efficacy.

The State of the Evidence

A systematic review by Pikov (2023) in the Journal of Translational Gastroenterology assessed neuromodulation — including VNS and sacral nerve stimulation — for IBD across the small body of available clinical studies. Its conclusion captures the field well: both approaches showed beneficial effects on IBD symptoms and on biomarkers of intestinal inflammation, with no significant long-term adverse effects, but the evidence base is small and early, and larger studies are needed to establish efficacy and the mechanisms involved.

In other words, the direction of the evidence is consistently positive, but the quantity and rigour are not yet sufficient to draw firm conclusions. Several signals pointing the same way is a reason to run larger, blinded trials — not a substitute for them.

Invasive Versus Non-Invasive

As with other inflammatory conditions, it is important to keep the two delivery methods distinct. The Crohn's disease pilot (Bonaz 2016) used an implanted device; the paediatric study (Sahn 2023) used a non-invasive ear device. The non-invasive route is far more appealing for a chronic condition that often affects young people, but its evidence base in IBD is the more preliminary of the two. Promising as the taVNS results are, they come from a single small proof-of-concept study with a largely uncontrolled efficacy phase.

What Is Still Missing

The distance between these encouraging signals and a proven therapy is mostly a matter of study design. Inflammatory bowel disease follows a relapsing-remitting course: symptoms and inflammation rise and fall on their own, and patients frequently improve for a time without any change in treatment. That makes uncontrolled, open-label data particularly hard to interpret, because a stretch of improvement during active stimulation may simply coincide with a natural remission that would have happened anyway.

This is why the largely open-label efficacy phases of the existing studies, promising as they are, cannot settle the question. What the field needs — and does not yet have at scale — is larger, randomised, sham-controlled trials with blinded outcome assessment and objective endpoints such as endoscopic healing and faecal calprotectin, followed long enough to span the disease's natural ups and downs. The value of the current work (Bonaz et al., 2016; Sahn et al., 2023) is that it justifies that investment, not that it substitutes for it. Several such trials, of both implanted and non-invasive devices, are underway, and they will determine whether the early signal holds up under proper scrutiny.

Symptom Relief Versus Mucosal Healing

In inflammatory bowel disease, not all improvement is equal, and this distinction shapes how the early VNS results should be read. Patients can feel better — fewer symptoms, less pain — without the underlying inflammation in the bowel wall actually resolving. Because symptoms fluctuate and respond to expectation, modern IBD research increasingly judges treatments against objective markers of inflammation: the endoscopic appearance of the gut lining (mucosal healing) and biochemical markers such as faecal calprotectin and C-reactive protein. These are harder to influence by placebo and correlate better with the long-term course of the disease.

This is why the most persuasive details in the existing VNS studies are not the symptom reports but the objective ones: the endoscopic healing and falling inflammatory markers seen in some of Bonaz's Crohn's patients, and the reductions in faecal calprotectin in Sahn's paediatric cohort. A measured drop in calprotectin carries more weight than a patient simply feeling better, because it points to genuine change in gut inflammation rather than perception alone.

The caveat is that these objective signals still came from small, largely uncontrolled studies, so they raise confidence without removing the need for blinded trials. But they matter for interpretation: they are part of why the IBD evidence, thin as it is, is taken more seriously than applications resting on subjective report alone — and future trials will be judged on exactly these endpoints. Faecal calprotectin in particular has become a standard, non-invasive way to track gut inflammation between colonoscopies, which makes it a practical and credible endpoint for the larger studies still needed.

Safety

Both implanted and non-invasive VNS have favourable safety profiles. The implanted device carries the usual minor risks of implant surgery, while taVNS produces mostly mild, transient effects such as local tingling — as covered in our review of the safety profile of VNS. The paediatric taVNS study reported good tolerability. None of this, however, speaks to effectiveness, which remains the open question.

The Bottom Line

Vagus nerve stimulation is a credible and actively investigated research direction for inflammatory bowel disease, supported by a coherent mechanism and several small studies pointing in a hopeful direction:

- The vagus nerve plausibly influences gut inflammation through the cholinergic anti-inflammatory pathway and the gut-brain axis (Tracey, 2002; Bonaz et al., 2018).
- An implanted-device pilot improved markers of Crohn's disease (Bonaz et al., 2016).
- A non-invasive taVNS proof-of-concept study reported remission and reduced inflammation in paediatric IBD, though its efficacy phase was largely uncontrolled (Sahn et al., 2023).
- A systematic review found consistent but early, small-scale evidence (Pikov, 2023).

The honest position is that this is early-stage, promising research — not an established treatment. Anyone with IBD interested in neuromodulation should discuss it with their gastroenterologist and should not substitute it for proven therapy. For a related early-stage gut application, see our article on VNS for irritable bowel syndrome, and browse the trials in our Evidence Database.

---

References

Bonaz, B. et al. (2016). Chronic vagus nerve stimulation in Crohn's disease: a 6-month follow-up pilot study. Neurogastroenterology & Motility, 28(6), 948–953.

Bonaz, B., Bazin, T. & Pellissier, S. (2018). The vagus nerve at the interface of the microbiota-gut-brain axis. Frontiers in Neuroscience, 12, 49.

Pikov, V. (2023). Vagus nerve stimulation and sacral nerve stimulation for inflammatory bowel disease: a systematic review. Journal of Translational Gastroenterology, 1(2), 94–100.

Sahn, B. et al. (2023). Transcutaneous auricular vagus nerve stimulation attenuates inflammatory bowel disease in children: a proof-of-concept clinical trial. Bioelectronic Medicine, 9, 23.

Tracey, K.J. (2002). The inflammatory reflex. Nature, 420(6917), 853–859.